Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oncolytics Biotech ( (ONCY) ) has shared an update.
Oncolytics Biotech Inc. announced on November 19, 2025, that it has aligned with the FDA on the design of a pivotal Phase 3 study for pelareorep in combination with standard-of-care therapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). This trial, set to launch in the first half of 2026, will be the only current registration trial involving an immunotherapy for first-line pancreatic cancer, potentially offering a new treatment option where immunotherapies have shown limited benefits. The study will evaluate pelareorep with chemotherapy, with or without a checkpoint inhibitor, and aims to demonstrate a clinically meaningful survival benefit.
The most recent analyst rating on (ONCY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA. Oncolytics is also pursuing strategic partnerships to accelerate development and maximize commercial impact.
Average Trading Volume: 1,039,754
Technical Sentiment Signal: Hold
Current Market Cap: $111.5M
For detailed information about ONCY stock, go to TipRanks’ Stock Analysis page.